At the request of French authorities in 2012, Merck KGaA reformulated levothyroxine — replacing the excipient lactose with mannitol and citric acid. However, failure to notify patients of the changes has led to thousands of complaints culminating in a police raid of Merck’s facility in Lyon, France. In a communique, the France’s health agency (ANSM) disclosed that the 14,633 reports received by pharmacovigilance officials represent 0.6% of the 2.6 million patients treated with the new formula.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
